Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07449936 · ClinicalTrials.gov registry record · Phase 3
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
A Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME), sponsored by EyePoint Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 3
- Study locations
NCT07449936 is a Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME) that is actively recruiting participants, run by EyePoint Pharmaceuticals. The registered enrollment target is 240 participants, below the 3,791-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07449936, a Phase 3 study of Diabetic Macular Edema and Diabetic Macular Edema (DME), is actively recruiting participants, sponsored by EyePoint Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions Studied
Interventions
- DRUG EYP-1901
- DRUG Aflibercept (2.0 mg)
Study Locations (3)
California
- Global Research Management, Inc. - Glendale
Indiana
- Midwest Eye Institute - Carmel - Carmel
Texas
- Mt. Olympus Medical Research - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07449936
The ClinicalTrials.gov registry entry for NCT07449936 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,791-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (94% lower). The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which EYP-1901 is the first listed.
NCT07449936 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT07449936 about?
NCT07449936 is a clinical study titled "COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME". This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
What is the current status of trial NCT07449936?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2026-02-26. Estimated completion is 2028-08.
What conditions does trial NCT07449936 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Macular Edema (DME), DME.
What interventions are being tested in trial NCT07449936?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept (2.0 mg) (DRUG).
Who is sponsoring clinical trial NCT07449936?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07449936 being conducted?
This trial has 3 study locations across California, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.